Core Insights - Radiopharm Theranostics has appointed Dr. Oliver Sartor to its Scientific Advisory Board, enhancing its expertise in oncology radiopharmaceuticals [1][5]. Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [1][5]. - The company is listed on ASX (RAD) and NASDAQ (RADX) and has a pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumor cancers, including lung, breast, and brain metastases [5]. Dr. Oliver Sartor's Background - Dr. Sartor is a recognized expert in prostate cancer and radiopharmaceutical therapies, currently serving as Director of Radiopharmaceutical Clinical Trials at Mayo Clinic [2][3]. - He has authored over 500 peer-reviewed publications and led pivotal Phase 3 trials that resulted in FDA approvals for several therapies [4]. Strategic Importance - The addition of Dr. Sartor to the Scientific Advisory Board is expected to provide invaluable insights and leadership as the company advances its radiopharmaceutical pipeline [5].